Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01342354 · ClinicalTrials.gov registry record · Phase 1
Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT01342354 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 15 participants.
The verdict
NCT01342354, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This purpose of this study is to determine the highest tolerated dose of Stereotactic Body Radiation Therapy (SBRT) and also to determine the appropriate dose for intact pancreatic cancer.
Interventions
- RADIATION Stereotactic Radiation 10 Gy
- RADIATION Stereotactic Radiation 12.5 Gy
- RADIATION Stereotactic Radiation 15 Gy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2009-04-14 |
| Est. Completion | 2022-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01342354
The ClinicalTrials.gov registry entry for NCT01342354 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Stereotactic Radiation 10 Gy is the first listed.
NCT01342354 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01342354 about?
NCT01342354 is a clinical study titled "Study of Stereotactic Body Radiation Therapy in Patients With Intact Pancreatic Cancer". This purpose of this study is to determine the highest tolerated dose of Stereotactic Body Radiation Therapy (SBRT) and also to determine the appropriate dose for intact pancreatic cancer.
What is the current status of trial NCT01342354?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2009-04-14. Estimated completion is 2022-06-01.
What interventions are being tested in trial NCT01342354?
The interventions under investigation include: Stereotactic Radiation 10 Gy (RADIATION), Stereotactic Radiation 12.5 Gy (RADIATION), Stereotactic Radiation 15 Gy (RADIATION).
Who is sponsoring clinical trial NCT01342354?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.